T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...
White blood cells in the GI tract known as intraepithelial lymphocytes express the gamma delta T cell receptor (gamma delta IELs), which prevent infection and provide surveillance for the ...
GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.
engineered natural killer cell and gamma delta T-cell candidates for blood cancers. The Big Pharma paid out $150 million in cash and an equity investment and offered up more than $3 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback